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Abstract
Benzene is an established cause of leukemia, and possibly lymphoma, in humans, but the underlying
molecular pathways remain largely undetermined. We used two microarray platforms to identify
global gene expression changes associated with well-characterized occupational benzene exposure
in the peripheral blood mononuclear cells (PBMC) of a population of shoefactory workers.
Differential expression of 2692 genes (Affymetrix) and 1828 genes (Illumina) was found and the
concordance was 50 % (based on an average fold-change ≥ 1.3 from the two platforms), with similar
expression ratios among the concordant genes. Four genes (CXCL16, ZNF331, JUN and PF4), which
we previously identified by microarray and confirmed by real-time PCR, were among the top 100
genes identified by both platforms in the current study. Gene Ontology analysis showed
overrepresentation of genes involved in apoptosis among the concordant genes while pathway
analysis identified pathways related to lipid metabolism. The two-platform approach allows for
robust changes in the PBMC transcriptome of benzene-exposed individuals to be identified.
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INTRODUCTION
Benzene is an established cause of leukemia and a possible cause of lymphoma in humans
[1]. A possible mechanism underlying these pathologies is the induction by benzene of genetic
changes leading to chromosome aberrations, translocations, aneuploidy and long-arm deletions
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[2,3] along with alterations in cell differentiation and immune surveillance. Benzene is
hematotoxic, causing a decrease in total white blood cells, granulocytes and lymphocytes even
among workers with relatively low-level exposure to benzene [4]. Benzene is thought to lower
blood cell counts via metabolite effects on hematopoietic progenitor cells [4,5]. Depression of
the mitogenic response of B and T lymphocytes, as well as impairment of macrophage activity,
also result from benzene exposure [6]. Damage to the bone marrow stromal microenvironment
is another aspect of benzene-associated hematoxicity [7,8]. Individual susceptibility to the
genotoxic and hematotoxic effects of benzene is mediated through polymorphisms in DNA-
repair genes [9], cytokine and cell adhesion genes [10], and genes involved in benzene
metabolism [4,11].
While pathological outcome and susceptibility studies have generated some understanding of
the mechanisms of action of benzene, global gene expression studies have the ability to inform
on a more detailed level the involvement of specific genes and molecular pathways. The p53-
dependent nature of benzene toxicity and carcinogenesis was revealed by examination of gene
expression changes in mouse bone marrow (BM) in response to a 2-week exposure to inhaled
benzene at 300 ppm [12]. Gene expression in mouse hematopoietic stem cells (HSC) exposed
to inhaled benzene (100 ppm) implicated a number of response pathways including apoptosis,
growth control of damaged HSC, repair of damaged DNA, and HSC growth arrest [13]. We
previously identified several genes (ZNF331, CXCL16, JUN, and PF4) altered by benzene in
peripheral blood mononuclear cells (PBMC) from benzene-exposed (>10 ppm) workers
compared with unexposed controls. The genes were identified by the application of
highthroughput microarray analysis to discover potential biomarkers and relatively low-
throughput real-time PCR for confirmation [3].
In order to confirm previous findings and to discover more differentially expressed genes
associated with benzene exposure, in the current study we analyzed more samples using the
Affymetrix microarray platform, and have expanded the study to include a second microarray
platform (Illumina). Recent reports have shown good inter-platform reproducibility of gene
expression measurements between these two platforms [14]. The approach integrates
highthroughput confirmation with discovery, helping to further elucidate genetic pathways and
mechanisms underlying hematoxicity induced by benzene exposure.
RESULTS
The PBMC transcriptome of 8 individuals occupationally exposed to benzene compared with
8 matched controls was examined on two microarray platforms. Distinct processing protocols
appropriate to each platform, from labeling through hybridization and detection, were applied.
Data was analyzed using a novel Quantile Transformation approach [15].
Cross-Comparison of Genes Associated with Benzene Exposure by Affymetrix and Illumina
Microarray Platforms
On the Affymetrix platform, 2692 genes (represented by 3549 probes) were differentially
expressed (raw p ≤ 0.05). Considering genes with expression levels altered by 1.5-fold or
greater, 65 genes were down-regulated while 180 genes were up-regulated. On the Illumina
platform, 1828 genes (1856 probes) were differentially expressed (raw p ≤ 005) Modification
of expression levels by 1.5-fold and higher occurred in 171 genes (88 down-regulated and 83
up-regulated). Supplementary Tables S1 and S2 contain lists of all genes identified as
significant by Affymetrix and Illumina platforms, respectively, and show multiple test
correction values. Among the Affymetrix data, 15 genes remained significant after multiple
testing using the Quantile Transformation (QT) approach while 1 gene among the Illumina
data remained significant.
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The subset of genes that was identified as differentially expressed (based on raw p-values) in
common by both platforms was determined using two approaches. First, only those genes
identified by each platform which were common to a stringent platform comparison reference
file (described in Material and Methods), were analyzed by the same approach used to analyze
the full complement of genes from each platform. This approach yielded 1345 significant genes
by Affymetrix and 1275 genes by Illumina, which were directly comparable based on the
reference file (supplementary Tables S3 and S4, respectively). We determined the number of
genes with a fold-change ≥ 1.3 (up or down) on both platforms and found a concordance of 35
% (189 genes), Figure 1A. We also determined the number of common genes with an average
fold-change ≥ 1.3 (from both platforms) and found a concordance of 50 % (272 genes), Figure
1B.
In the second, less stringent approach, all of the significant genes identified by each platform
(2692 by Affymetrix and 1828 by Illumina) were compared by gene symbol. We determined
the number of genes with a fold-change ≥ 1.3 on both platforms in this less stringent data set
and found a concordance of 35 % (241 genes), Figure 1C. As above, we also determined the
number of common genes with an average fold-change ≥ 1.3 (from both platforms) and found
a concordance of 50 % (346 genes) similar to that obtained in the stringent comparison dataset,
Figure 1D.
All concordant genes are listed in supplementary Table S5. Expression ratios were similar
among the concordant genes (mean difference in expression ratio = 0.13, standard deviation =
0.12). Among the common genes, 57 genes were down-regulated while 66 genes were up-
regulated, by 1.5-fold or greater. Four genes (CXCL16, ZNF331, JUN and PF4), which we
previously identified by microarray and confirmed by real-time PCR, were identified by both
platforms in the current study. JUN and ZNF331 are among the top 20 common genes (ranked
by p-value) which are listed in Table 1. Both of these genes remained significant after correction
for multiple testing (Quantile Transformation) of the Affy data set (JUN QT-p = 0.044; ZNF331
QT-p = 0.042), while ZNF331 remained significant (QT-p = 0.039) and JUN (QT-p = 0.072)
approached significance upon correction of the Illumina data set. Other genes of note among
the top 20 are HSPA1A and HSPA1B, members of the heat-shock 70 (HSP70) multigene family.
Classification of Genes by Gene Ontology and Pathway Analyses
Several GO categories were identified by GOstat as enriched among both the Affymetrix and
Illumina datasets (genes with ≥ 1.5-fold up- or down-regulation). These GO categories, as well
as their associated genes, are listed in Table 2 and include immune response, defense response,
and response to stress, suggesting concordance between the two platforms at the functional
level. Genes involved in apoptosis were significant among the Affymetrix dataset but not the
Illumina dataset. Among the genes identified by both platforms, GOstat analysis showed
significant association with the GO term apoptosis (GO:0006915; p-value of 0.0113), but only
when all genes were included regardless of the magnitude of the fold-change.
Ingenuity canonical pathway analysis identified significant pathways among the common
genes as well as among the significant genes from both platforms. Significant pathways and
associated genes are shown in Table 3. Lipid metabolism was a key theme among the common
genes with involvement of ganglioside biosynthesis, glycerolipid metabolism,
glycerphospholipid metabolism and sterol biosynthesis pathways. From the Affymetrix dataset
protein ubiquitination was strongly impacted with 23 genes up-regulated and 4 genes down-
regulated. Among the Illumina dataset multiple pathways were involved as shown in Table 3.
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Evaluation of Transcripts Discordant between Platforms
As described above the overall concordance between the two platforms was 35-50 %. The most
significant genes (Top 50 by p-value) identified by either platform were more likely to be
ranked as significant by the other platform. Thus of the top 50 genes identified by Illumina, 31
genes were ranked as significant by Affymetrix, raising the concordance to 62 %. Similarly,
27 of the top 50 genes identified by Affymetrix also appeared in the Illumina dataset
(concordance 59 %).
Some genes, which were significant on one platform, approached significance on the other
platform. For example, C3AR1, which was up-regulated 2-fold on Affymetrix, approached
significance on the Illumina platform (p-value = 0.056, ratio 1.38). In the case of FYN, which
was up-regulated significantly (1.4-fold) by Affymetrix, the Illumina platform also detected
up-regulation (1.2-fold) but only approached significance (p = 0.07) and therefore did not
appear in the list of common genes. As both of these genes were present in the stringent
comparison file, this suggests that the two platforms may differ in their ability to detect small
changes in expression for specific probes.
DISCUSSION
We identified robust changes in gene expression in response to benzene exposure in 8
occupationally exposed individuals compared with 8 unexposed controls, by cross-comparison
using two microarray platforms (Affymetrix and Illumina). This approach enabled
identification of a greater number of robust biomarkers than our previous approach of single-
platform array analysis in conjunction with quantitative PCR confirmation.
A total of 346 genes were cross-validated by our two-platform approach. Further validation
was provided by the fact that four genes (CXCL16, ZNF331, JUN and PF4), which we
previously showed to be highly significantly associated with benzene exposure [3], were
present in the cross-validated dataset from the current study. JUN was previously shown to be
down-regulated by benzene exposure in mouse HSC [13]. Expression of FOSB expression was
also down-regulated (~1.6-fold) by both platforms in the current study. JUN and FOS are basic
regionleucine zipper (bZIP) members of the AP-1 transcription complex [16], which modulates
the decision of a cell to proliferate, differentiate, or die by apoptosis [17]. Since JUN promotes
proliferation of many cell types [17], reduced levels of JUN could indicate that the PBMCs of
benzene-exposed individuals are not proliferating or progressing through the cell cycle as
quickly as those of non-exposed individuals. Platelet Factor 4 (PF4), a chemokine secreted
from activated platelets [18], activated T cells and mast cells [19], is a chemoattractant for
neutrophils and fibroblasts and plays a role in inflammation and wound repair. PF4 was down-
regulated in the current study in agreement with previous observations [3,20].
We used gene ontology and pathway analyses to discern potential underlying biology from the
data. GO analysis showed enrichment in genes involved in apoptosis among the 346 common
genes, while pathway analysis identified an impact on lipid metabolism. Plasma cholesterol
(and phospholipids) were found previously to be slightly elevated in rat liver following a 28-
day oral benzene exposure [21]. Lipid levels have been shown to be altered in hematological
disorders including acute leukemia and non-Hodgkin lymphoma [22], CLL [23] and ALL
[24] and might represent a novel therapeutic target [23]. It is unclear whether changes in lipid
metabolism are causal in malignancy or arise as a consequence of the disease process. It is
known that changes in lipid metabolism occur during infection and that TNF and other
cytokines are capable of altering lipid metabolism in a variety of tissues leading to
hypertriglyceridemia [25,26]. The potential link between benzene exposure, lipid metabolism
and leukemogenesis is unclear. One possibility is that maintenance of the phopsholipid
membrane may be compromised during oxidative stress arising from benzene exposure.
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The fact that PBMC profiling reflects liver gene expression is not surprising in view of a recent
study showing that the peripheral blood transcriptome dynamically reflects systems wide
biology with 83% of liver genes also expressed in blood [27]. Genes involved in the GO
categories of immune response, stress response and defense response were enriched in the
separate platform datasets, with overlap of genes between platforms. Therefore, despite the
fact that concordance between the microarray platforms was 35-50 %, several mechanisms
(concordance at the pathway level) underlying benzene effects in human PBMC are in close
agreement and fit well with the phenotypic effects of benzene including decreased blood cell
counts [5], and depression of the immune system [6].
Chromatin assembly was identified as an overrepresented GO category in the Illumina data
only. If confirmed, it could represent a potential mechanism by which benzene causes leukemia
as histone proteins are involved in the regulation of DNA transcription, replication, repair and
recombination and post-translational modifications on histone tails epigenetically regulate the
genome-wide transcriptome. Reduction of histone levels such as by the Human T
Lymphotropic Virus Type 1 protein, Tax [28], ionizing radiation (IR) [29], adriamycin [29],
and if confirmed, benzene, may directly induce chromosomal instability and deregulate gene
expression, leading to cancer. Reduced histone levels have been proposed to have similar
effects to those observed with loss of imprinting (LOI) through DNA hypomethylation,
including aberrant chromosome rearrangements, deregulation of cellular gene expression and
activation of latent viral genomes [28]. Chromatin structure, nucleosome remodeling and
histone tail modifications influence double-strand DNA break repair [30-33] and defects in
chromatin assembly have been shown to impair double-strand break repair and activate S phase
arrest [34,35].
In the current study the Bax:Bcl2 ratio, an indicator of the degree of apoptosis was 1:0.5,
suggesting a shift towards apoptosis. Down-regulation of two anti-apoptotic hsp70-encoding
genes [36] was also observed in the current study. Increased apoptosis is a mechanism that
could potentially underlie benzene-associated leukemia, one theory being that cells escape
from apoptosis with DNA breaks which can result in chromosomal translocation [37-39], and
induction of apoptosis in hematopoietic progenitor cells [40,41] and cell lines [42] by benzene
metabolites has been previously demonstrated. Removal of cells predestined to die by apoptosis
is facilitated, at least in some tissues by macrophages [43,44], and dysfunction of macrophages
may lead to survival of cells that would otherwise have been removed. Poisoning of the BM
stromal environment [7], particularly macrophages [8], is a hematotoxic effect of benzene.
While overall concordance between the two microarray platforms was 35-50 %, the most
significant genes identified by either array were much more likely to be ranked as significant
by the other platform. While very high concordance levels have been reported (~90%) between
the Affymetrix and Illumina platforms, these were based on extremely different biological
samples with large fold changes in expression [14]. Smaller concordance levels were seen
when comparing less biologically similar samples [14] or analyzing rat toxicogenomic data
[45]. Our study was based on occupationally-exposed individuals with inherent inter-individual
variability in baseline expression, determined by factors such as blood count, blood type,
genotype, presence of subclinical infection [46], which are less easy to control for by study
design as are factors such as age and gender. Other explanations of microarray data discordance
have been discussed [14,47]. Our inter-platform concordance is higher than that of two studies
using a similar approach to ours, which showed average concordances of 22.8% [48] and ~10%)
[49].
As well as concordance among individual genes, similar mechanisms of benzene effect such
as response to stress and immune response were found in our study. However the results
potentially caution against use of a single platform to identify biomarkers/pathways in human
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exposure studies, in which subtle perturbations may be detected. Our data also suggest the need
to be very stringent in the selection of potential biomarkers based on a single platform as
platform concordance was much higher among the most highly significant genes.
Challenges are inherent to this type of molecular epidemiology study. While many potential
biomarkers of benzene exposure were generated, few genes remained significant after multiple
testing (QT p-value ≤ 0.05). Another challenge is the biological relevance of small fold-changes
in gene expression. Increasing the number of individuals studied is one way to increase the
power to select true biomarkers. Cross-comparison by two platforms increases the chances that
the genes identified in our study represent true potential biomarkers, but validation of
biomarkers in a larger population is also necessary, at both the RNA and protein levels. While
limited sample material precluded the validation of the microarray findings by QPCR in the
current study, use of two microarray platforms offers a type of inherent validation in that
distinct processing protocols appropriate to each platform, from labeling through hybridization
and detection, were applied.
The question of the appropriateness of PBMC as a cell target in which to examine benzene's
hematotoxic effects must also be addressed. While some of benzene's immunotoxic effects are
thought to involve damage to BM stromal cells [7] and early progenitor cells [4] the knock-on
effects of damage to these cells might be expected to be manifest in the transcriptome of their
downstream cell targets. As discussed above, the peripheral blood transcriptome dynamically
reflects system wide biology [27]. However, relevant changes may be masked by looking at
heterogenous populations of cells e.g. BM compared with HSC [13]. Many of the genes
identified in this study are expressed in several cell types and have pleiotropic effects, making
it challenging to induce function and mechanism when examining PBMC. Further, as benzene
exposure has been shown to decrease all types of white blood cells and platelets, by 16%
(lymphocytes) to 35.8% (B cells) [4], some of the observed changes in expression could reflect
these altered cell populations. However, PBMC are convenient for molecular epidemiology
research studies and pathways and mechanisms identified as potentially impacted by benzene
exposure such as apoptosis, can be further tested in in vitro studies using targeted cell subsets.
In conclusion, we have demonstrated robust changes in the PBMC transcriptome of benzene-
exposed individuals, using a two-platform approach. The genes identified contribute to further
understanding of the mechanisms underlying benzene-induced hematoxicity and leukemia.
MATERIALS AND METHODS
Study Subjects
Eight highly exposed workers (mean air benzene level ± SD = 39.0 ± 25.5 ppm) and eight
unexposed controls (<0.04 ppm) who were frequency-matched to these subjects on the basis
of age and gender, were chosen from a large molecular epidemiology study [50] investigating
occupational exposure to benzene. Six subject pairs (twelve individuals) were included in a
previous study [3] and another pair was chosen to give a better balance among the subjects for
the confounders of age and gender. The study was approved by institutional review boards at
all institutions. Participation was voluntary, written informed consent was obtained, and the
participation rate was approximately 95%.
Four pairs were male and the other four female. Mean age was 33.5 ± 7.0 years for the eight
exposed workers and 35.4 ± 7.0 years for the controls. Four of the exposed workers and one
of the control workers were smokers. Mean white blood cell count (mean ± SD cells/μL blood)
was 4812.5 ± 974.6 for the exposed workers compared with 5762.5 ± 1785.6 for controls
(normal range for Chinese population 4000 - 10,000). Similarly, in the exposed workers
granulocyte (2862.5 ± 652.3) and platelet (160750 ± 36405.5) counts were lower than in the
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control workers (granulocyte 3562.5 ± 1261.5, platelet 209875 ± 74299.5), but still within the
normal range for the Chinese population (2000 - 8000, 100,000 - 361,500, respectively).
Hemoglobin (g/L) was 139.9 ± 15.5 in the exposed workers and 145.8 ± 19.5 in the controls
(normal range 110 - 170). Among all 390 subjects (140 controls and 250 benzene-exposed) in
the overall molecular epidemiology study, all types of white blood cells (WBCs) measured and
platelets were significantly decreased in workers exposed to >10 ppm benzene (and also in
those exposed to doses as low as <1ppm benzene) compared to controls [4]. Exposure
assessment, biologic sample collection and RNA isolation were described previously [3,4].
Workers had been employed an average of 6.1 ± 2.9 years and individual benzene exposure
was monitored repeatedly up to 16 months before phlebotomy. A single RNA isolation was
performed from each individual and stored in aliquots.
Affymetrix microarray analysis
The Affymetrix Human U133 GeneChip set containing ~44,000 probes targeting >39,000
unique transcripts derived from approximately 33,000 well-substantiated genes, are included
in this chip set. The complete protocol used for Affymetrix microarray analysis was described
previously [3].
Illumina Microarray analysis
RNA samples, with A260:A280 ratios between 1.7 and 2.1, and with integrity confirmed by
denaturing agarose gel electrophoresis, were labeled using the Illumina® RNA Amplification
kit (Ambion, Austin, TX). Samples were reverse transcribed in 20μL reactions comprising 200
ng sample RNA, 1X First Strand Buffer, dNTPs, RNase inhibitor, and ArrayScript enzyme.
Reactions were incubated at 37°C for 2 hr after which components of the second strand
synthesis reaction including 10X Second Strand Buffer, dNTP mix, DNA polymerase, and
RNase H were added to yield a final reaction volume of 100μL. Reactions were incubated at
16°C for 2hr and the resulting cDNAs were purified. cDNA binding buffer (250μL) was added
to each reaction which was then mixed and passed through a cDNA filter cartridge by
centrifugation at 10,000 × g for 1 min. Filters were washed with wash Buffer (500μL) and
dried by centrifugation for an additional minute. cDNA was eluted using 2 × 10μL aliquots of
Nuclease-free Water at 55°C. The purified cDNA was dried to completion in a vacuum
centrifuge concentrator set to medium heat and resuspended in 10μL in vitro transcription
(IVT) reaction mix comprising 1X reaction buffer, dNTP mix, biotin labeled UTP (10 mM;
Roche Applied Science, Indianapolis, IN), and T7 enzyme. Reactions were incubated at 37°C
for 14 hr after which volumes were adjusted to 100μL by addition of Nuclease-free water.
cRNA Binding Buffer (350μL) and 100% ethanol (250μL) were added and mixed by pipetting
before passing through a cRNA filter cartridge under centrifugation at 10,000 × g for 1 min.
Filters were washed with wash Buffer (650μL) and dried by centrifugation for an additional
minute. cDNA was eluted using 100μL of Nuclease-free Water at 55°C. cRNA was quantified
using nce-based assay the RiboGreen® fluorescence-based assay (Invitrogen, Carlsbad, CA).
Hybridization, washing and detection were performed using the Illumina Gene Expression
System Buffer Kit for HumanRef-8 BeadChips (Illumina, San Diego, CA) according to the
manufacturer's protocol. An aliquot containing 850 ng cRNA was transferred to a new tube
and adjusted to a volume of 11.3 μL. Hybridization Mix was prepared by mixing Hyb E1 buffer
(125 μL), which had been prewarmed in a 55°C oven for 10 min, to formamide (75μL).
Hybridization Mix (22.7 μL) was added to each cRNA sample. Following sample incubation
at 65°C for 5 min, 34 μL was dispensed onto the center of each HumanRef-8 BeadChip onto
array. BeadChips were assembled onto Hybridization cartridges, mixed by shaking to ensure
bubbles moved freely, and then placed on the BeadChip Hyb Wheel and incubated for 16 hr
at 55°c rotation.
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Following hybridization, a manual washing procedure was followed in which BeadChips were
placed in a slide rack and washed in supplied solutions in glass staining dishes. Slide racks
were plunged in and out of the appropriate solution 5-10 times and then mixing was performed
on an orbital shaker (Thermolyne Roto Mix, Type 50800, Barnstead International, Dubuque,
IA) at highest possible speed or on a rocker shaker (Rocker II 260350, Boekel Scientific,
Feasterville, PA) at medium-high speed, for the times indicated. Following hybridization,
slides were washed successively in wash E1BC solution (250 mL), 100% ethanol (250 mL),
and fresh Wash E1BC solution (250 mL), with 15 min, 10 min and 2 min orbital shaking,
respectively. In order to block the slides, BeadChips were placed face-up in a wash tray
(supplied) containing Block E1 buffer (4 mL) and rocked for 10 min. For detection BeadChips
were transferred to a fresh wash tray containing Block E1 buffer (2 mL) containing streptavidin-
Cy3 (1μg/mL; Amersham Biosciences, Piscataway, NJ) and rocked for 10 min. Slides were
then placed in a staining rack and washed in Wash E1BC solution (250 mL) with 5 minutes of
orbital shaking. The slides were then dried by centrifugation at 275 × g for 4 min at 20°C in a
Jouan CR4.22 centrifuge (Thermo Electron Corporation, Waltham, MA) and stored in the dark
until scanned. Scanning was performed using a BeadArray Reader and BeadScan software
(Illumina).
Data Analysis
Raw data files for each microarray experiment have been deposited at GEO, accession number
Series GSE9569 (GSM241938 through GSM243811) and access is available at:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dhovtgesoygsyng&acc=GSE9569.
Data was normalized by quantile normalization using Bioconductor (Affymetrix data by RMA
and Illumina data by “Affy” package) and two-sample Welch t-statistics (unequal variance)
were calculated. We used a multiple testing procedure that controls familywise error rates
(FWER) and has been shown to provide sharp control (for instance relative to the standard
Bonferroni procedure) by accounting for the strong correlation of gene expression measures
typically observed in microarray studies [51]. It works using a re-sampling based technique
(bootstrapping) to generate a sample of the test statistics from the empirical joint distribution
of the data and then quantile transforms these random samples into the appropriate marginal
null distribution (in this case, the t-distribution). Then, the observed test statistics are compared
to the maximum of each random draw from this null distribution to derive the estimated FWER
for various cut-offs in a list ordered by statistical significance. In the supplementary tables, we
also provide the more traditional (and typically conservative) methods for reporting FWER.
Comparison of array platforms
In order to determine comparable targets from the Affymetrix (Human U133 GeneChip set;
~45,000 probe sets targeting 39,000 transcripts from 33,000 well-substantiated genes) and
Illumina (HumanRef-8 BeadChip; > 23,000 RefSeq-curated gene targets) platforms, probe
sequences from each platform and transcript sequences from RefSeq Release 13
(http://www.ncbi.nlm.nih.gov/RefSeq/) were compared. For both platforms, probes that were
not valid were filtered out. A probe was defined as valid if it perfectly matched a transcript
sequence and did not perfectly match any other transcript sequences with a different gene
symbol. If a transcript sequence contained multiple valid probes, the one closest to the 3' end
of the transcript was selected. As cDNA synthesis is primed by olgodT primers from the polyA
tails of the mRNAs, this minimizes the effects of RNA degradation on cDNA integrity. Based
on these criteria 14,708 targets were included in the cross-platform analysis.
In a second approach, all the significant genes identified by each platform (2692 by Affymetrix
and 1828 by Illumina) were subjected to an ID conversion program called Gene Expression
Pattern Analysis Suite v3.1 (http://www.gepas.org) [52] and significant gene lists were then
compared by gene symbol.
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Gene RefSeq accession numbers were imported into Ingenuity Pathway Analysis software
(Ingenuity® Systems, Redwood City, CA, (www.ingenuity.com) a web-based application,
which queries the Ingenuity Pathway Knowledge Base (IPKB) for genetic interactions. To
evaluate the significance of the association of a particular gene set with the relevant canonical
pathway within Ingenuity, a ratio of the number of genes from the data set that map to the
pathway divided by the total number of genes that map to the canonical pathway is displayed
and Fischer's exact test is used to calculate the corresponding p-value.
Gene Ontology Analysis
A publicly available tool was applied to assess enrichment of Gene Ontology (GO) terms over
that which would be expected by chance alone. In GOstat [50], a χ2 test is used to generate a
p-value. Adjustment for multiple comparisons is based on False Discovery Rate (FDR).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Concordance between platforms in the identification of genes induced by benzene exposure.
The numbers of significant genes (P ≤ 0.05) from the analysis of differential expression
performed by t-test/quantile transformation (QT) are shown. A. Genes with fold-change ≥ 1.3-
fold on both platforms, based on the stringent comparison data set. B. Genes with an average
fold-change ≥ 1.3-fold, based on the stringent comparison data set. C. Genes with a fold-change
≥ 1.3-fold on both platforms, based on the complete data set. D. Genes with an average fold-
change ≥ 1.3-fold, based on the complete data set.
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